Investors & Media
Ryvu Therapeutics has a track record of creating significant value for shareholders since its listing on the NewConnect market in 2011 and the subsequent IPO on the main market of Warsaw Stock Exchange in 2014. The company has delivered strong return on the combined $91M investment from private, public market investors, including over $36M raised in the Series I shares offering in July 2020.
Ryvu has been consequently demonstrating research progress, bringing novel drug candidates to the clinic, including SEL24/MEN1703 initiating Phase II studies and RVU120 progressing through Phase I, as well as additionally raising over $88M in non-dilutive grant funding to support its research efforts.
We value investor communications very highly and we build our investor relationships on trust and transparency. Ryvu is audited by EY and is subject to regulatory oversight of the Polish Financial Supervisory Authority, under the European Union and the Polish laws. Ryvu technological expertise is validated by global partnerships with Merck KGaA, Galapagos, Menarini Group and Leukemia & Lymphoma Society.
In 2016, Ryvu has spun out its NALP3 inflammasome assets to NodThera, founded by life science investor, Epidarex Capital. In total, the project aimed at the development of inflammasome inhibitors discovered by Ryvu and spun off to NodThera, has already raised over £80 million (over $98 million) of funding. Ryvu remains a shareholder in the Company. For more information about NodThera see: www.nodthera.com.
In July 2020, Ryvu Therapeutics has moved its entire operations to its new headquarters, newly built R&D Centre for Innovative Drugs, located at 2 Sternbacha Street, in Krakow.
Quick Access
Corporate Overview
Ryvu Milestones
2007
- Company founded (as Selvita)
2010
- First global partnering contract with Orion Pharma (as Selvita S.A.)
2011
- Listed on NewConnect market (WSE)
2013
- Beginning of oncology partnership with Merck KGaA
2014
- IPO on Warsaw Stock Exchange
2015
- Spin-out of Ardigen – precision medicine & AI services company
2016
- Inflammasome assets spun-out to Nodthera
2017
- Initiation of SEL24/MEN1703 study in acute myeloid leukemia
- Global license agreement with Menarini Group for SEL24/MEN1703
- Partnership with the Leukemia & Lymphoma society for RVU120 development
2018
- Successful Completion of $41 M Book Building
2019
- Ryvu divests its CRO business into Selvita
- Initation of RVU120 study in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)
2020
- SEL24/MEN1703 initiates Phase II studies
- Orphan Drug Designation for RVU120 to treat Acute Myeloid Leukemia
- Galapagos and Ryvu announce research collaboration
- Ryvu moves to the newly built R&D Centre for Innovative Drugs
- Completion of $36 M share issue
- Expansion of SEL24/MEN1703 Phase I/II study to Europe
2021
- Expansion of Phase I study of RVU120 in patients with AML or HRMDS to Poland
2007
- Company founded (as Selvita)
2010
- First global partnering contract with Orion Pharma (as Selvita S.A.)
2011
- Listed on NewConnect market (WSE)
2013
- Beginning of oncology partnership with Merck KGaA
2014
- IPO on Warsaw Stock Exchange
2015
- Spin-out of Ardigen – precision medicine & AI services company
2016
- Inflammasome assets spun-out to Nodthera
2017
- Initiation of SEL24/MEN1703 study in acute myeloid leukemia
- Global license agreement with Menarini Group for SEL24/MEN1703
- Partnership with the Leukemia & Lymphoma society for RVU120 development
2018
- Successful Completion of $41 M Book Building
2019
- Ryvu divests its CRO business into Selvita
- Initation of RVU120 study in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)
2020
- SEL24/MEN1703 initiates Phase II studies
- Orphan Drug Designation for RVU120 to treat Acute Myeloid Leukemia
- Galapagos and Ryvu announce research collaboration
- Ryvu moves to the newly built R&D Centre for Innovative Drugs
- Completion of $36 M share issue
- Expansion of SEL24/MEN1703 Phase I/II study to Europe
2021
- Expansion of Phase I study of RVU120 in patients with AML or HRMDS to Poland
Contact For Investors
-
Media & Investor Inquries
ir@ryvu.com -
Clinical Inquries
clinicaltrials@ryvu.com